How did Corcept Therapeutics' revenue and expenses trend in Q4 2024?

Corcept Therapeutics experienced a decline in revenue and an increase in expenses during Q4 2024 compared to the previous quarter.

1. Revenue Trend: The company's revenue decreased by approximately 4.33% to $675.04 million in Q4 2024, down from the previous quarter's revenue of $493.15 million. This indicates a contraction in sales and a potential impact on business performance.
2. Expense Trend: The Cost of Goods Sold remained at $2.96 million, which did not change significantly. However, the Selling, General, and Administrative Expenses increased to $83.37 million, up from the previous quarter's $70.3 million. This suggests that despite the revenue decline, operational costs have risen, potentially affecting profitability.
3. Net Income: The company reported a Net Income of $30.75 million in Q4 2024, which is a notable figure considering the revenue decline. This indicates that Corcept Therapeutics was able to maintain profitability despite the challenges in revenue growth.